Edwards to sell critical care products unit to Becton Dickinson for $4.2 bln
Adds analyst comment in paragraph 3 and background paragraph 4 onwards
By Pratik Jain
June 3 (Reuters) -Edwards Lifesciences EW.N on Monday said it has agreed to sell its critical care products unit to Becton Dickinson BDX.N in an all-cash deal valued at $4.2 billion to sharpen focus on its heart devices business.
Edwards is no longer pursuing theplanned spin-off of thecritical care unit, which develops and sells advanced blood and heart monitoring systems that are used in surgical and intensive care settings, announced in April.
"The transaction creates a pure-play structural heart company positioning Edwards for strategic initiatives that could further create shareholder value," RBC Capital Markets analyst Shagun Singh said in a note.
California-based Edwards has been facing fierce competition for its Transcatheter aortic valve replacement (TAVR) devices, the company's lead product. These devices are usedto perform minimally invasive surgery for people with heart valve disease.
Edwards intends to use the after-tax cash proceeds to expand opportunities for its heart devices and invest in new technologies.
The unit, which generated $928 million in revenue last year, also sells other patient monitoring products, sensors and catheters, as well as predictive software and apps.
Becton Dickinson said the deal was consistent with the company's 2025 M&A strategy, which seeks "growth-enhancing and value-creating tuck-ins."
The buyout is expected to be immediately accretive to all key financial measures, including Becton Dickinson's revenue growth, and adjusted earnings per share, it added.
New Jersey-based Becton expects to fund the all-cash transaction with about $1 billion of cash and $3.2 billion of new debt.
The transaction is expected to close by the end of 2024, subject to the satisfaction or waiver of certain closing conditions.
Shares of Edwards were up 1.6%, while Becton rose about 3% in early morning trade following announcement.
Reporting by Pratik Jain in Bengaluru; Editing by Tasim Zahid
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
